A Phase 2/3 interventional study of adalimumab and Placebo in Crohn's Disease, sponsored by Abbott. Completed at 29 sites in Japan. Open to participants aged 15 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-02-02.
Sponsored by Abbott · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.
Among the 42 studies testing adalimumab in Crohn Disease, this one is the 29th largest by enrollment, is one of 4 that started in 2007, is one of 2 in phase 2/3, and was the 11th registered.
1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 6–17
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18–70
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 15 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 24 · Phase 4 13
First in 2002; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 82 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 143 across the 42 interventional studies. Of the 32 that completed or were terminated, 19 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 42 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
17 studies in Crohn Disease by Abbott: none open now, none under way, none of them phase 3. Of 17 finished, 9 (53%) have results posted.
Among the 17 studies in Crohn Disease by Abbott, this one is the 15th largest by enrollment, is one of 5 that started in 2007, is one of 2 in phase 2/3, and was the 14th registered.
Abbott’s Crohn Disease studies by the year they started, since 2002.
1 of the studies testing adalimumab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing adalimumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 17 in Crohn Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate the efficacy and safety of adalimumab for the maintenance of clinical remission in Japanese subjects with Crohn's disease.
This was a Phase 2/3, multicenter, randomized, double-blind (DB), placebo-controlled, two-arm, efficacy, safety, and pharmacokinetic study designed to demonstrate the effectiveness of adalimumab in Japanese patients with moderate to severe Crohn's Disease (CD).
All participants who had completed Study M04-729 (NCT00445939), the lead-in adalimumab induction therapy study, were eligible for this study. Participants who rolled over into this study received either DB treatment (adalimumab or placebo) or open-label (OL) treatment with adalimumab.
Crohn's Disease Activity Index (CDAI) was used to determine participants who were responders and participants who were in clinical remission. CDAI documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. It yields a total score >= 0 and without upper limit. Baseline scores in the study ranged from 221 to 448. Low score=less severe CD activity. Decrease in score indicates improvement.
Clinical remission is a CDAI score \< 150.
Clinical response-70 (CR-70) = decrease in CDAI ≥ 70 points from lead-in study Baseline score.
Clinical response-100 (CR-100) = decrease in CDAI ≥ 100 points from lead-in study Baseline score.
Participants who had CR-70 response at Week 4 of the induction study were randomized into 1 of 2 treatment groups (double-blind adalimumab 40 mg every other week or adalimumab placebo every other week) using 2 stratification factors - CDAI category (CDAI less than 150 and CDAI 150 or higher) and presence/absence of fistula at Week 0 of this study. The double-blind treatment was to last from Week 0 to Week 52. Any time at or after Week 4 of this study, if a participant's disease flared (defined as a recurrence of very active disease, specifically an increase in CDAI when compared to Week 0 in this study of ≥ 70 points and a CDAI above 220) during the double-blind treatment period, the participant was allowed to move to OL treatment. At Week 52, all participants still receiving DB treatment were to be moved to open-label treatment and could continue in the study until adalimumab is approved for commercial use in Japan.
Participants who did not respond by Week 4 in the induction study and participants who had disease flare during DB treatment of this study entered OL treatment and received adalimumab 40 mg every other week. At or after Week 4 of this study, if a participant in the open-label treatment group had a disease flare or if the participant was still not responding to treatment, the participant was allowed to dose escalate to adalimumab 80 mg every other week. Participants who entered open-label treatment were to be allowed to continue on open-label adalimumab until adalimumab is approved for commercial use in Japan.
The study is complete. Results of this study are reported for endpoints at Week 52 (end of the DB treatment period) for subjects who received DB treatment (adalimumab or placebo) or OL adalimumab treatment and for endpoints at Week 148 for all subjects who received at least one dose of adalimumab in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects received double-blind (DB) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the DB treatment period lasting 52 weeks.
Biological: adalimumab
Subjects received placebo subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
Other: Placebo
Subjects received open-label (OL) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
Biological: adalimumab
Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)
Also known as: Humira, D2E7
Subcutaneous injection of placebo (0.8 mL/injection) every other week (eow)
Number of Participants Who Had Clinical Remission at Week 52 of Double-blind Treatment
Clinical remission=Crohn's Disease (CD) Activity Index (CDAI) \<150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is \>= 0 and without upper limit. Low score=less severe CD activity. Decrease indicates improvement.
Time frame: Week 52 of double-blind treatment
Number of Participants Who Had Clinical Response-70 (CR-70; a Decrease in Crohn's Disease Activity Index of at Least 70 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment
Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.
Time frame: Week 52 of double-blind treatment
Number of Participants Who Had Clinical Response-100 (CR-100; a Decrease in Crohn's Disease Activity Index of at Least 100 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment
Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.
Time frame: Week 52 of double-blind treatment
Change in Crohn's Disease Activity Index From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment
Crohn's Disease Activity Index (CDAI) is a measure of disease severity. Number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.
Time frame: Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment
Number of Participants Who Had Clinical Remission at Week 52 of Open-label Treatment
Clinical remission=Crohn's Disease (CD) Activity Index (CDAI) \<150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.
Time frame: Week 52 of open-label treatment
Change in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment
The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) score is an indicator of the activity of Crohn's disease. It measures absence (score of 0) or presence (score of 1) of abdominal pain, diarrhea or bloody stools more than 6 times per day, anal lesion, anal fistula, other complication, abdominal mass, weight loss, fever above 38 degrees Centigrade, abdominal tenderness, and blood pigment below 10 g/dL. Total possible score=0 to 10; low score=less disease activity. Decrease in score indicates alleviation of the disease; increase indicates aggravation of disease.
Time frame: Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment
IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period. It has 32 questions about bowel function and related symptoms, and their social and emotional impact. For each item, participants select 1 of 7 responses. 1=poor quality of life (e.g., feeling of fatigue "all of the time") and 7=good quality (e.g., feeling of fatigue "none of the time"). Scoring range = 32 to 224. Higher scores indicate better quality of life; increases in IBDQ = improved overall quality of life.
Time frame: Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment
Change in Physical Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment
The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain, and rating of one's health. Score on the physical component ranges from 0 (Poorest Health) to 100 (Best Health).
Time frame: Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment
Change in Mental Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment
The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation. The mental component reflects energy/vitality, social functioning, limitations, and ratings of one's mental health. Score on mental component ranges from 0 (worst score) to 100 (best score).
Time frame: Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment
Number of Participants Who Had Clinical Remission at Week 148
Clinical remission = Crohn's Disease (CD) Activity Index (CDAI) \<150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is \>= 0 and without upper limit. Low score=less severe CD activity. Decrease indicates improvement.
Time frame: Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
Number of Participants Who Had Clinical Response-70 (CR-70; a Decrease in Crohn's Disease Activity Index of at Least 70 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 148
Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.
Time frame: Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
Number of Participants Who Had Clinical Response-100 (CR-100; a Decrease in Crohn's Disease Activity Index of at Least 100 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 148
Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.
Time frame: Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
Change in Crohn's Disease Activity Index From Baseline of Lead-in Study (NCT00445939) to Week 148
Crohn's Disease Activity Index (CDAI) is a measure of disease severity. Number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/apthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI has a total score \>=0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.
Time frame: Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
Change in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of Lead-in Study (NCT00445939) to Week 148
The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) score is an indicator of the activity of Crohn's disease. It measures absence (score of 0) or presence (score of 1) of abdominal pain, diarrhea or bloody stools more than 6 times per day, anal lesion, anal fistula, other complication, abdominal mass, weight loss, fever above 38 degrees Centigrade, abdominal tenderness, and blood pigment below 10 g/dL. Total possible score=0 to 10; low score=less disease activity. Decrease in score indicates alleviation of the disease; increase indicates aggravation of disease.
Time frame: Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of Lead-in Study (NCT00445939) to Week 148
IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period with 32 questions about bowel function and related symptoms \& their social/emotional impact. Per item, participants select 1 of 7 responses (1=poor quality of life \[e.g., feeling of fatigue "all of the time"\]; 7=good quality \[e.g., feeling of fatigue "none of the time"\]). Scoring range=32 to 224. Higher scores indicate better quality of life; increases in IBDQ=improved overall quality of life.
Time frame: Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
Change in Physical Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 148
The Short Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain, and rating of one's health. Score on the physical component ranges from 0 to 100, with 0=Poorest Health and 100=Best Health.
Time frame: Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
Change in Mental Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 148
The Short Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 indicates alleviation of the disease and a decrease in score indicates aggravation. The mental component reflects energy/vitality, social functioning, limitations, and ratings of one's mental health. Score on mental component ranges from 0 (worst score) to 100 (best score).
Time frame: Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
| Milestone | DB Adalimumab 40 mg Eow | Placebo Eow | OL Adalimumab 40 mg Eow | Any Adalimumab |
|---|---|---|---|---|
| Started | 25 | 25 | 32 | 0 |
| Completed | 10 | 2 | 21 | 0 |
| Not completed | 15 | 23 | 11 | 0 |
| Withdrew: Adverse event | 1 | 2 | 7 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 0 |
| Withdrew: Moved to open-label | 14 | 20 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 2 | 0 |
| Milestone | DB Adalimumab 40 mg Eow | Placebo Eow | OL Adalimumab 40 mg Eow | Any Adalimumab |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 79 |
| Completed | 0 | 0 | 0 | 35 |
| Not completed | 0 | 0 | 0 | 44 |
| Withdrew: Adverse event | 0 | 0 | 0 | 32 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 3 |
| Withdrew: Other | 0 | 0 | 0 | 9 |
Clinical remission=Crohn's Disease (CD) Activity Index (CDAI) \<150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is \>= 0 and without upper limit. Low score=less severe CD activity. Decrease indicates improvement.
| Participants | DB Adalimumab 40 mg Eow | Placebo Eow |
|---|---|---|
| Number of Participants Who Had Clinical Remission at Week 52 of Double-blind Treatment | 8 | 2 |
Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.
| Participants | DB Adalimumab 40 mg Eow | Placebo Eow | OL Adalimumab 40 mg Eow |
|---|---|---|---|
| Number of Participants Who Had Clinical Response-70 (CR-70; a Decrease in Crohn's Disease Activity Index of at Least 70 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment | 9 | 2 | 10 |
Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.
| Participants | DB Adalimumab 40 mg Eow | Placebo Eow | OL Adalimumab 40 mg Eow |
|---|---|---|---|
| Number of Participants Who Had Clinical Response-100 (CR-100; a Decrease in Crohn's Disease Activity Index of at Least 100 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment | 8 | 2 | 8 |
Crohn's Disease Activity Index (CDAI) is a measure of disease severity. Number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.
| units on a scale | DB Adalimumab 40 mg Eow | Placebo Eow |
|---|---|---|
| Change in Crohn's Disease Activity Index From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment | -83.7 ± 110.26 | -9.1 ± 110.41 |
Clinical remission=Crohn's Disease (CD) Activity Index (CDAI) \<150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.
| Participants | OL Adalimumab 40 mg Eow |
|---|---|
| Number of Participants Who Had Clinical Remission at Week 52 of Open-label Treatment | 5 |
The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) score is an indicator of the activity of Crohn's disease. It measures absence (score of 0) or presence (score of 1) of abdominal pain, diarrhea or bloody stools more than 6 times per day, anal lesion, anal fistula, other complication, abdominal mass, weight loss, fever above 38 degrees Centigrade, abdominal tenderness, and blood pigment below 10 g/dL. Total possible score=0 to 10; low score=less disease activity. Decrease in score indicates alleviation of the disease; increase indicates aggravation of disease.
| units on a scale | DB Adalimumab 40 mg Eow | Placebo Eow |
|---|---|---|
| Change in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment | -0.8 ± 1.89 | -0.2 ± 1.34 |
IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period. It has 32 questions about bowel function and related symptoms, and their social and emotional impact. For each item, participants select 1 of 7 responses. 1=poor quality of life (e.g., feeling of fatigue "all of the time") and 7=good quality (e.g., feeling of fatigue "none of the time"). Scoring range = 32 to 224. Higher scores indicate better quality of life; increases in IBDQ = improved overall quality of life.
| units on a scale | DB Adalimumab 40 mg Eow | Placebo Eow |
|---|---|---|
| Change in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment | 27.8 ± 32.44 | 1.8 ± 35.42 |
The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain, and rating of one's health. Score on the physical component ranges from 0 (Poorest Health) to 100 (Best Health).
| units on a scale | DB Adalimumab 40 mg Eow | Placebo Eow |
|---|---|---|
| Change in Physical Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment | 4.4 ± 9.09 | 0.2 ± 6.31 |
The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation. The mental component reflects energy/vitality, social functioning, limitations, and ratings of one's mental health. Score on mental component ranges from 0 (worst score) to 100 (best score).
| units on a scale | DB Adalimumab 40 mg Eow | Placebo Eow |
|---|---|---|
| Change in Mental Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment | 9.6 ± 8.37 | 0.3 ± 14.15 |
Clinical remission = Crohn's Disease (CD) Activity Index (CDAI) \<150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is \>= 0 and without upper limit. Low score=less severe CD activity. Decrease indicates improvement.
| participants | Any Adalimumab |
|---|---|
| Number of Participants Who Had Clinical Remission at Week 148 | 21 |
Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.
| participants | Any Adalimumab |
|---|---|
| Number of Participants Who Had Clinical Response-70 (CR-70; a Decrease in Crohn's Disease Activity Index of at Least 70 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 148 | 28 |
Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.
| participants | Any Adalimumab |
|---|---|
| Number of Participants Who Had Clinical Response-100 (CR-100; a Decrease in Crohn's Disease Activity Index of at Least 100 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 148 | 26 |
Crohn's Disease Activity Index (CDAI) is a measure of disease severity. Number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/apthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI has a total score \>=0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.
| units on a scale | Any Adalimumab |
|---|---|
| Change in Crohn's Disease Activity Index From Baseline of Lead-in Study (NCT00445939) to Week 148 | -143.0 ± 102.49 |
The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) score is an indicator of the activity of Crohn's disease. It measures absence (score of 0) or presence (score of 1) of abdominal pain, diarrhea or bloody stools more than 6 times per day, anal lesion, anal fistula, other complication, abdominal mass, weight loss, fever above 38 degrees Centigrade, abdominal tenderness, and blood pigment below 10 g/dL. Total possible score=0 to 10; low score=less disease activity. Decrease in score indicates alleviation of the disease; increase indicates aggravation of disease.
| units on a scale | Any Adalimumab |
|---|---|
| Change in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of Lead-in Study (NCT00445939) to Week 148 | -1.7 ± 1.41 |
IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period with 32 questions about bowel function and related symptoms \& their social/emotional impact. Per item, participants select 1 of 7 responses (1=poor quality of life \[e.g., feeling of fatigue "all of the time"\]; 7=good quality \[e.g., feeling of fatigue "none of the time"\]). Scoring range=32 to 224. Higher scores indicate better quality of life; increases in IBDQ=improved overall quality of life.
| units on a scale | Any Adalimumab |
|---|---|
| Change in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of Lead-in Study (NCT00445939) to Week 148 | 27.2 ± 31.22 |
The Short Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain, and rating of one's health. Score on the physical component ranges from 0 to 100, with 0=Poorest Health and 100=Best Health.
| units on a scale | Any Adalimumab |
|---|---|
| Change in Physical Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 148 | 5.44 ± 7.245 |
The Short Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 indicates alleviation of the disease and a decrease in score indicates aggravation. The mental component reflects energy/vitality, social functioning, limitations, and ratings of one's mental health. Score on mental component ranges from 0 (worst score) to 100 (best score).
| units on a scale | Any Adalimumab |
|---|---|
| Change in Mental Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 148 | 6.44 ± 11.173 |
Collected over 52 weeks for the double-blind (DB) treatments (adalimumab and placebo) and for the open-label adalimumab treatment. Overall study (maximum adalimumab treatment of 184 weeks plus 70-day follow-up period) for the Any Adalimumab group.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Adalimumab 40 mg Eow | — | 2/25 (8%) | 17/25 (68%) |
| Placebo Eow | — | 6/25 (24%) | 13/25 (52%) |
| OL Adalimumab 40 mg Eow | — | 13/32 (40.6%) | 28/32 (87.5%) |
| Any Adalimumab | — | 49/79 (62%) | 73/79 (92.4%) |
| Event | DB Adalimumab 40 mg Eow | Placebo Eow | OL Adalimumab 40 mg Eow | Any Adalimumab |
|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 1/25 | 3/25 | 9/32 | 26/79 |
| Abdominal abscessInfections and infestations | 1/25 | 0/25 | 0/32 | 4/79 |
| IleusGastrointestinal disorders | 0/25 | 0/25 | 0/32 | 4/79 |
| Intestinal obstructionGastrointestinal disorders | 1/25 | 0/25 | 1/32 | 3/79 |
| Intestinal perforationGastrointestinal disorders | 0/25 | 1/25 | 0/32 | 2/79 |
| SubileusGastrointestinal disorders | 0/25 | 1/25 | 0/32 | 0/79 |
| Liver abscessInfections and infestations | 0/25 | 1/25 | 0/32 | 0/79 |
| Perianal abscessInfections and infestations | 0/25 | 1/25 | 0/32 | 1/79 |
| SomnolenceNervous system disorders | 0/25 | 1/25 | 0/32 | 0/79 |
| PeritonitisGastrointestinal disorders | 0/25 | 0/25 | 0/32 | 3/79 |
| Event | DB Adalimumab 40 mg Eow | Placebo Eow | OL Adalimumab 40 mg Eow | Any Adalimumab |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 14/25 | 3/25 | 23/32 | 60/79 |
| Adverse drug reactionGeneral disorders | 3/25 | 1/25 | 6/32 | 22/79 |
| PyrexiaGeneral disorders | 2/25 | 1/25 | 3/32 | 17/79 |
| Dental cariesGastrointestinal disorders | 3/25 | 1/25 | 3/32 | 16/79 |
| HeadacheNervous system disorders | 1/25 | 2/25 | 4/32 | 16/79 |
| Crohn's diseaseGastrointestinal disorders | 2/25 | 4/25 | 4/32 | 15/79 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/25 | 0/25 | 6/32 | 12/79 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 4/25 | 0/25 | 0/32 | 8/79 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 0/25 | 0/25 | 4/32 | 11/79 |
| InsomniaPsychiatric disorders | 0/25 | 0/25 | 0/32 | 10/79 |
| Age, Categorical(Participants) | DB Adalimumab 40 mg Eow | Placebo Eow | OL Adalimumab 40 mg Eow | Total |
|---|---|---|---|---|
| <=18 years | 0 | 2 | 3 | 5 |
| Between 18 and 65 years | 25 | 23 | 29 | 77 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age Continuous(years) | DB Adalimumab 40 mg Eow | Placebo Eow | OL Adalimumab 40 mg Eow | Total |
|---|---|---|---|---|
| Mean | 31.60 ± 7.171 | 30.80 ± 10.939 | 30.75 ± 8.359 | 31.02 ± 8.808 |
| Sex: Female, Male(Participants) | DB Adalimumab 40 mg Eow | Placebo Eow | OL Adalimumab 40 mg Eow | Total |
|---|---|---|---|---|
| Female | 9 | 10 | 14 | 33 |
| Male | 16 | 15 | 18 | 49 |
| Region of Enrollment(participants) | DB Adalimumab 40 mg Eow | Placebo Eow | OL Adalimumab 40 mg Eow | Total |
|---|---|---|---|---|
| Japan | 25 | 25 | 32 | 82 |
The record gives a start of Mar 2007, a primary completion of Mar 2009 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab